Radiobiology with proton cyclotron beams: a viability study by Cunha, Micaela dos Santos
Imagem 
 
 
 
 
Micaela dos Santos Cunha 
 
 
RADIOBIOLOGY WITH PROTON 
CYCLOTRON BEAMS: A VIABILITY STUDY 
 
  
 
Dissertação de Mestrado na área científica de Engenharia Biomédica, especialidade Imagem e Radiação, orientada pelo 
Professor Doutor Rui Ferreira Marques, Professor Doutor Francisco Alves e Professor Doutor Paulo Crespo e apresentada 
ao Departamento de Física da Faculdade de Ciências e Tecnologia da Universidade de Coimbra. 
 
Setembro de 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Radiobiology With Proton Cyclotron Beams:
A Viability Study
Faculty of Sciences and Technology
University of Coimbra
To obtain the degree
of Master of Science in Biomedical Engineering
M.Sc. dissertation Micaela dos Santos Cunha
from Santo Tirso, Portugal
Coimbra 2010
Supervisor: Prof. Dr. Rui Ferreira Marques
Co-supervisor: Prof. Dr. Paulo Crespo
Co-supervisor: Prof. Dr. Francisco Alves
Submission date: 06.09.2010
Public examination date: 14.09.2010
Para os que sempre me apoiaram.

Index
List of Figures iii
List of Tables v
List of Acronyms and Abbreviations vii
Sumário ix
Motivação . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix
Summary xi
Motivation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xi
1 Radiotherapy With Protons 1
1.1 Motivation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Brief history . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.3 Rationale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.3.1 Physical rationale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.3.2 Radiobiological rationale . . . . . . . . . . . . . . . . . . . . . . . . . . 8
1.4 Comparison with photons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.5 Comparison with other charged particles . . . . . . . . . . . . . . . . . . . . . 10
1.6 Equipment and facilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.6.1 Accelerators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
1.6.2 Treatment delivery systems . . . . . . . . . . . . . . . . . . . . . . . . . 13
2 Simulation Tools for the Development of a Proton Radiobiological Setup 17
2.1 Geant4 and SRIM/TRIM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.2 Validation of Geant4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.2.1 Proton range . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.2.2 Proton beam lateral scattering . . . . . . . . . . . . . . . . . . . . . . . 20
3 Concept for a Proton Cyclotron-Based Radiobiology Facility 23
3.1 ICNAS cyclotron . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
3.2 Design proposal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
3.3 Influence of beam divergence on dose delivery . . . . . . . . . . . . . . . . . . . 25
3.3.1 Pencil beam . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
3.3.2 Beam with dispersion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
4 Conclusions 37
4.1 Work results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
4.2 Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
i
ii Index
Appendices 41
A Software and hardware used 43
A.1 Hardware . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
A.2 Geant4 simulation toolkit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
A.3 Other software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
B Havar® 47
Bibliography 48
Acknowledgments 55
List of Figures
1.1 Cancer incidence and mortality rates worlwide per 100 000 population . . . . . 1
1.2 Prediction of the number of cases of cancer in 2030 . . . . . . . . . . . . . . . . 2
1.3 Depth-dose profiles for photons, carbon ions and protons . . . . . . . . . . . . . 3
1.4 Spread-out Bragg peak produced from several pristine Bragg peaks . . . . . . . 4
1.5 Energy loss in water for several particles . . . . . . . . . . . . . . . . . . . . . . 6
1.6 Lateral broadening of a photon, carbon and proton beam . . . . . . . . . . . . 7
1.7 Characteristic cell survival pattern for X-rays and charged particles or neutrons 8
1.8 Definition of the relative biological effectiveness, with cell survival curves . . . . 9
1.9 Comparison of the irradiation of a medulloblastoma with X-rays and with protons 10
1.10 The relative biological effectiveness for heavy ions . . . . . . . . . . . . . . . . . 11
1.11 Floor plan of the proton therapy centers in Loma Linda and Heidelberg . . . . 12
1.12 Scheme of the nozzle at the Francis H. Burr Proton Therapy Center . . . . . . 13
1.13 Comparison between intensity modulated therapy with photons and protons . . 14
2.1 Representation of the simulation setup for proton range validation . . . . . . . 18
2.2 Range in water for 18-MeV protons, obtained using TRIM . . . . . . . . . . . . 18
2.3 Range of 18-MeV protons in a 5-mm long water target. . . . . . . . . . . . . . . 19
2.4 Schematic illustration of the simulation setup for proton beam width validation 20
2.5 Angular distribution of protons after traversing 1.5 mm of water . . . . . . . . 22
3.1 Dose-response curve for tumor control and normal tissue damage probability . . 23
3.2 Concept of the experimental setup being planned . . . . . . . . . . . . . . . . . 25
3.3 Depth-dose profile in water for 18-MeV protons . . . . . . . . . . . . . . . . . . 26
3.4 Influence of density variation on depth-dose profile in water for 18- and 17.5-MeV
protons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.5 Influence of proton beam energy on depth-dose profile in water . . . . . . . . . 28
3.6 Representation of the simulation setup for irradiating water with 200-MeV protons 28
3.7 Influence of water density on depth-dose profile in water for 200-MeV protons . 29
3.8 Representation of the simulation setup for first simulations of a beam with dis-
persion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.9 Depth-dose profiles in water at different radius for 17- and 17.5-MeV protons . 31
3.10 Representation of the simulation setup for calculating the dose 3D distribution 32
3.11 Depth-dose profile and 2D distribution of 17-MeV protons in water . . . . . . . 33
3.12 Representation of the simulation setup for studying the influence of Havar® on
dose 3D distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
3.13 Influence of Havar® on depth-dose profile and 2D distribution of 17-MeV protons
in water . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
4.1 Schematic representation of a setup configuration to allow for the delivery of low
doses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
iii
iv List of Figures
List of Tables
1.1 List of all currently operating proton therapy facilities . . . . . . . . . . . . . . 5
1.2 Quantities relevant for the Bethe-Bloch equation and some of their values . . . 6
2.1 Some of the values used for calculating beam lateral scattering . . . . . . . . . 21
2.2 Parameters used to fit the simulated data to a pseudo-Voigt function . . . . . . 21
4.1 Relevant positron-emitter production reactions . . . . . . . . . . . . . . . . . . 40
A.1 Machines used to perform the simulations . . . . . . . . . . . . . . . . . . . . . 43
B.1 Nominal composition of Havar® . . . . . . . . . . . . . . . . . . . . . . . . . . 47
B.2 Physical properties of Havar® . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
v
vi List of Tables
List of Acronyms and Abbreviations
2D / 3D 2 Dimension(al) / 3 Dimension(al)
ASR Age-Standardized Rate
CATANA Centro di AdroTerapia e Applicazioni Nucleari Avanzate, Catania, Italy
DNA Deoxyribonucleic Acid
EBRT External Beam Radiation Therapy
FTPI Florida Proton Therapy Institute, Jacksonville, FL, USA
FWHM Full Width at Half Maximum
GSI Gesellschaft für Schwerionenforschung, Darmstadt, Germany
HIBMC Hyogo Ion Beam Medical Center, Hyogo, Japan
HIT Heavy Ion Therapy, Heidelberg, Germany
HMI Hahn-Meitner-Institut Berlin, Berlin, Germany
HZB Helmholtz Zentrum Berlin für Materialien und Energie, Berlin, Germany
IBA Ion Beam Applications, S.A., Louvain-la-Neuve, Belgium
ICNAS Instituto de Ciências Nucleares Aplicadas à Saúde, Coimbra, Portugal
IMRT Intensity Modulated Radiation Therapy
IMPT Intensity Modulated Proton Therapy
INFN-LNS Istituto Nazionale di Fisica Nucleare - Laboratori Nazionali del Sud,
Catania, Italy
ITEP Institute for Theoretical and Experimental Physics, Moscow, Russia
LBNL Lawrence Berkeley National Laboratory, Berkeley, CA, USA
LET Linear Energy Transfer
LINAC Linear Accelerator
LIP Laboratório de Instrumentação e Física Experimental de Partículas,
Coimbra, Portugal
MCS Multiple Coulomb Scattering
MGH Massachusetts General Hospital, Boston, MA, USA
MPRI Midwest Proton Radiotherapy Institute, Bloomington, IN, USA
NCC National Cancer Center, Kashiwa, Japan
NCC National Cancer Center, Ilsan, South Korea
NPTC Northeast Proton Treatment Center, Boston, MA, USA
vii
viii List of Acronyms and Abbreviations
OAR Organ at Risk
PET Positron Emission Tomography
PMRC Proton Medical Research Center, Tsukuba, Japan
PTV Planning Treatment Volume
PSI Paul Scherrer Institute, Villigen, Switzerland
RBE Relative Biological Effectiveness
RPC Resistive Plate Chamber
RPTC Rinecker Proton Therapy Center, Munich, Germany
SOBP Spread-Out Bragg Peak
SRIM The Stopping and Range of Ions in Matter
TRIM The Transport of Ions in Matter
TRIUMF TRI-University Meson Facility, Vancouver, Canada
UCSF University of California, San Francisco, CA, USA
WERC The Wakasa Wan Energy Research Center, Tsuruga, Japan
WPTC Wanjie Proton Therapy Center, Zibo, China
Sumário
Motivação
O número de centros de radioterapia com protões está a aumentar em todo o mundo, com trinta
centros actualmente em operação e mais de vinte em fase de planeamento ou já em construção.
Os resultados da radioterapia com protões estão a despertar o interesse de cada vez mais
centros médicos, num número crescente de países, em disponibilizá-la aos seus doentes. Ao
mesmo tempo, ciclotrões capazes de acelerar protões até cerca de 20 MeV têm sido instalados
por todo o mundo. Embora o seu propósito seja principalmente a produção de radioisótopos
para tomografia por emissão de positrões, eles estão equipados com várias linhas de feixe que
podem ser utilizadas para investigação científica. Cada linha de feixe pode dar tipicamente
correntes de 150 A (1x1015 partículas/s). Fazer estudos radiobiológicos usando estas linhas
de feixe pode contribuir para o melhoramento dos resultados da radioterapia com protões,
nomeadamente por dar novos dados para a resposta a algumas questões ainda por esclarecer:
 o impacto do fraccionamento da radioterapia com partículas na eficácia da dose, incluindo
os diferentes efeitos nas regiões irradiadas no pico de Bragg versus no patamar;
 a influência das respostas dos tecidos vivos, como o edema, o encolhimento do tumor,
o dano vascular com consequente permeabilidade aumentada, e processos inflamatórios
com consequentes alterações na densidade dos tecidos;
 o efeito adjuvante e/ou tóxico do uso de compostos farmacêuticos em concomitância com
a radioterapia;
 as causas da hipersensibilidade a baixas doses de radiação [Ste07b, Sch10];
 os mecanismos por detrás do efeito bystander ou efeito bystander induzido por radiação,
e das chamadas respostas adaptativas [Mot04, Wid09]; e
 a evolução espacial e temporal do dano provocado pela radiação, a qual pode ser avaliada
através da evolução espacial e temporal das quebras da cadeia dupla de ADN [Sch10].
Novos dados para responder a estas e outras questões podem contribuir para a melhoria dos
resultados da radioterapia e consequentemente para a redução das taxas de mortalidade em
doentes com cancro.
Neste trabalho estudamos a viabilidade da implementação de um sistema experimental numa
das linhas de feixe do ciclotrão de 18 MeV recentemente instalado no Instituto de Ciências
Nucleares Aplicadas à Saúde, Universidade de Coimbra. Esse sistema deve permitir a realização
de estudos radiobiológicos, incluindo os efeitos da irradiação com protões em culturas celulares
e animais de pequeno porte.
Várias simulações baseadas em Monte Carlo foram desenvolvidas no Geant4 para optimizar o
sistema em estudo. Estas foram inicialmente validadas contra outro software como o SRIM/TRIM
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e também contra resultados teóricos publicados. Os cálculos de dose foram feitos usando difer-
entes configurações para avaliar perfis de dose-profundidade e distribuições 2D.
Summary
Motivation
The number of proton radiotherapy facilities is increasing througout the world, with thirty
centers currently operational and more than twenty in a planning stage or already under con-
struction. Proton therapy outcomes are triggering the interest of more and more medical
facilities, of a crescent number of countries, in making it available for their patients. At the
same time, cyclotrons capable of accelerating protons up to about 20 MeV have been world-
wide installed. Although their purpose is mainly positron emission tomography radioisotope
production, they are equipped with several beam lines that may be used for scientific research.
Each beam line may typically deliver proton currents up to 150 A (1x1015 particles/s). Radio-
biological studies using of these beam lines may contribute to further improve proton therapy
results, namely by giving input to some unclear questions, namely:
 the impact of fractionation of particle radiotherapy on dose effectiveness including differ-
ent effects in regions irradiated in the Bragg peak versus the plateau;
 the influence of living tissue responses such as edema, tumor shrinkage, vascular damage
with consequent increased permeability, and inflammatory processes with consequent
changes in tissue density;
 the adjuvant and/or toxic effects of using pharmaceutical compounds in concomitance
with radiotherapy;
 the causes of hypersensitivity to low doses of radiation, a phenomenon called low-dose
hyper-radiosensitivity [Ste07b, Sch10];
 the mechanisms underlying the bystander effect or radiation-induced bystander effect and
the so-called adaptative responses [Mot04, Wid09]; and
 the spatial and temporal evolution of radiation damage, which can be evaluated through
the spatial and temporal evolution of DNA double-strand breaks [Sch10].
Input to these and other issues could contribute to the further improvement of radiotherapy
outcomes and consequently to the decrease of mortality rates in cancer patients.
In this work we study the viability of implementing an experimental setup at one of the beam
lines of the 18-MeV proton cyclotron recently installed at Instituto de Ciências Nucleares
Aplicadas à Saúde, University of Coimbra, Portugal. Such setup should allow radiobiological
studies to be performed, including the effects of proton irradiation on cell cultures and small
animals.
Several Monte Carlo simulations based on Geant4 were deployed to optimize the setup under
study. These were initially validated with against packages such as SRIM/TRIM and also
xi
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against theoretical published results. Dose calculations were performed using different config-
urations to evaluate depth-dose profiles and dose 2D distributions.
Chapter 1
Radiotherapy With Protons
1.1 Motivation
Cancer is a major concern in today’s society, as more than one in three people will have
cancer during their lifetime [CRU10b]. Only in 2008 almost 13 million new cases of cancer
were registered and almost 8 million people died all over the world due to this disease [Fer10].
Furthermore, about three-quarters of all cases of cancer are developed by people with 60 years
and over who represent 10% of the total world population nowadays and are expected to
represent 22% in 2050. This fact combined with the prospective of increase of life expectancy
from the current 65 years to 76 years in 2050, means that the number of occurrences of cancer
will be higher in the future, admitting that the current rates of incidence (age-standardized
Figure 1.1: Cancer incidence and mortality rates per 100 000 population of both sexes and
all ages in several regions of the world; after [Fer10]. Data for all types of cancer excluding
non-melanoma skin cancer in age-standardized rates (ASR).
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Figure 1.2: Prediction of the number of cases of cancer in 2030 for men and women of all ages
worldwide. The prediction is performed by adding the expected demographic effect for the year
2030 to the number of cases of cancer registered in 2008; after [Fer10].
rates (ASR1) in Fig. 1.1) remain the same [CRU10a]. Fig. 1.2 shows a prediction of the number
of cases of cancer in 2030 for men and women of all ages based on the numbers of 2008 and
adding the expected demographic effect.
Looking at these statistics, specially at those concerning cancer mortality, one can realize how
important it is to create and improve the existing conditions for people with cancer to have
the highest probabilities of being cured or, at least, get palliative treatment. Radiotherapy
plays a major role when it comes to cancer treatment, either curative or palliative. It can
be administered alone or in a multimodality plan, usually in conjunction with surgery and/or
chemotherapy. For example, in the United Kingdom 40% of the patients cured from cancer
were treated with radiotherapeutical means [Boa03] and worldwide more than 50% of all cancer
patients need to receive radiation therapy during their treatment [Boy08, Fow06, Sch06].
Radiotherapy has greatly improved since its early days, by the time of the discovery of the
X-rays by Roentgen in 1895, and it is still in progress nowadays [Fow06]. All issues involved
in treatment planning like patient positioning, dose calculation, tumor volume definition and
localization, and the treatment technique are under constant research, so that the goal of
radiotherapy can be fulfilled, i.e., to kill the tumor with the lowest possible damage to the sur-
rounding healthy tissue [Sch06]. Furthermore, therapy with radiation is not limited to external
beam radiation therapy (EBRT) and definitely not limited to photons and electrons. There
are other options to consider such as brachytherapy, charged particle therapy, and neutron
therapy, just to name a few. In particular, proton and carbon ion therapy are two topics of
great interest nowadays. These particle techniques are characterized by a property not shared
by photons and electrons, the Bragg peak, which allows for a higher deposition of energy in the
target volume while lowering the dose to the vicinity. This characteristic may allow improving
cancer treatment results, thereby contributing to the reduction of the mortality rates due to
cancer.
1 An age-standardized rate is a summary measure of the rate that a population would have if it had a standard
age structure [Fer10]. The ASR is a weighted mean of the age-specific rates; the weights are taken from
population distribution of the standard population. The most frequently used standard population is the
World Standard Population. The calculated incidence or mortality rate is then called age-standardized
incidence or mortality rate (world). It is also expressed per 100 000.
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Figure 1.3: Depth-dose profiles for photons, carbon ions and protons; from [Lag07].
1.2 Brief history
Protons and heavier ions1 were suggested as a possibility for radiation treatment for the first
time in 1946, by Robert Wilson [Wil46], who thought that the depth-dose distribution presented
by these particles would be adequate to treat tumors in humans. Unlike photons and electrons,
these particles show a low and nearly flat energy deposition which increases with the penetration
depth until it reaches a maximum called the Bragg peak, and then falls steeply to approximately
zero (Fig. 1.3). This means protons and heavier charged particles will cause, towards the end
of their range, higher ionization than photons or electrons of comparable energy, enabling
the delivery of a higher dose to a deep-seated tumor, while sparing the surrounding healthy
tissues. Protons, because distal to the tumor the energy deposition falls to zero, delivers no
dose beyond the tumor [Kra00, Smi06]. Carbon and other heavy charged particles show an
increased relative biological effectiveness (RBE) that potentiates their action mainly in the
Bragg peak, in addition to a smaller lateral scattering and range straggling [Kra00].
Wilson also proposed a technique widely used today to encase all the volume of large tumors,
using a range modulation wheel to produce a spread-out Bragg peak (SOBP). In Fig.1.4 we
can see a SOBP built up from several pristine2 Bragg peaks.
As soon as 1954, radiotherapy with protons started to be an option available to cancer patients
at the Lawrence Berkeley National Laboratory (LBNL) [Tob58]. After some previous animal
experiments [Tob52, Tob42] Tobias and his colleagues irradiated the first patient for a pitu-
itary treatment with proton beams from the ’184- inch Synchrocyclotron’ built by Lawrence
and Edlefsen in 1930 [Law30]. By 1957 radiotherapy with protons commenced in Europe at
the University of Uppsala in Sweden, where a broad spectrum of cancers were treated, such
as glioblastoma multiforme, carcinomas of the cervix, nasopharynx, head and neck, among
others [Fal62]. Larsson and his team were the first to implement Wilson’s idea of modulating
the proton beam and producing a SOBP by designing the adequate ridge filters and they also
were the first to use beam scanning to produce large treatment fields in the lateral dimen-
sion [Lar61]. Other proton therapy facilities were implemented in several countries like Russia
(Dubna, 1967), Japan (Chiba, 1979), and Switzerland (Villigen, 1984) [Sui07, Smi06] in the
following 30 years after the irradiation of the first patient at LBNL. Proton therapy has grown
1 Ions heavier than protons are called heavy in radiobiology, as opposed to nuclear physics terminology, due
to their increased biological effectiveness [Kra00].
2 A pristine Bragg peak is the one measured for a single energy beam [She08].
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Figure 1.4: Spread-out Bragg peak (SOBP) produced from several pristine Bragg peaks through
range and intensity modulation. SOBPs can be achieved using a physical device (ridge filter or
modulation wheel) or selecting the energy from the accelerator and weighting each individual
Bragg peak; from [Smi06].
significantly with about 67 000 patients treated to date worldwide [Jer10]. Table 1.2 lists all
centers in operation in 2010.
1.3 Rationale
When we refer to the rationale for using protons in radiotherapy we are evoking both the
physical rationale and the radiobiological rationale. The former has to do with the physical
processes that occur when the proton interacts with matter in general, and the latter pertains
to the reactions (and its consequences) at a cellular level.
1.3.1 Physical rationale
As previously mentioned in section 1.2, protons were considered an option to radiotherapy due
to their depth-dose profile [Wil46]. This profile, the Bragg curve, shows a narrow peak near
the end of the particles track, which makes protons suitable for the treatment of deep-seated,
inoperable, radioresistant, and/or close to organs at risk (OAR) tumors. This characteristic
profile is explained by protons interaction with matter, which at this energy level are known
to be mainly Coulomb interactions with bound atomic electrons. This electronic energy loss
is described by the Bethe-Bloch equation (equation 1.1), which gives the mean rate of energy
loss (or stopping power) [Nah07a, Kra00, Nak10]:
  dE
dx
= Kz2eff
Z
A
1
2

1
2
ln
2mec
222Tmax
I2
  2   
2

(1.1)
where Tmax is the maximum kinetic energy that can be imparted to a free electron in a single
collision. The other quantities are defined in Table 1.2.
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Table 1.1: List of all currently operating proton therapy facilities; adapted from [pFa10].
Max. Start
Clinical Beam of Total
Who, Where Country Energy, Direction Treat- Patients
MeV ment Treated
ITEP, Moscow Russia 250 horiz. 1969 4162
St.Petersburg Russia 1000 horiz. 1975 1353
PSI, Villigen Switzerland 72 1 horiz. 1984 5300
Dubna Russia 200**** horiz. 1999 595
Uppsala Sweden 200 1 horiz. 1989 929
Clatterbridge England 62 1 horiz. 1989 1923
Loma Linda CA.,USA 250 3 gantry, 1 horiz. 1990 14000
Nice France 65 1 horiz. 1991 3935
Orsay France 200 2 horiz. 1991 4811
iThemba Labs South Africa 200 1 horiz. 1993 511
MPRI(2) IN.,USA 200 2 gantry, 1 horiz. 2004 890
UCSF CA.,USA 60 1 horiz. 1994 1200
TRIUMF, Vancouver Canada 72 1 horiz. 1995 145
PSI, Villigen** Switzerland 250* 1 gantry 1996 542
HZB (HMI), Berlin Germany 72 1 horiz. 1998 1437
NCC, Kashiwa Japan 235 2 gantry 1998 680
HIBMC, Hyogo Japan 230 gantry 2001 2382
PMRC(2), Tsukuba Japan 250 gantry 2001 1586
NPTC, MGH Boston USA 235 2 gantry, 1 horiz. 2001 4270
INFN-LNS, Catania Italy 60 1 horiz. 2002 174
Shizuoka Japan 235 gantry, horiz. 2003 852
WERC, Tsuruga Japan 200 1 horiz.,vertical 2002 56
WPTC, Zibo China 230 2 gantry, 1 horiz. 2004 977
MD Anderson Cancer
Center, Houston*** USA 250 3 gantry, 1 horiz. 2006 1700
FPTI, Jacksonville USA 230 3 gantry, 1 horiz. 2006 1847
NCC, IIsan South Korea 230 2 gantry, 1 horiz. 2007 519
RPTC, Munich** Germany 250 4 gantry, 1 horiz. 2009 78
ProCure Proton Therapy
Center, Oklahoma City USA 230 gantry, horiz. 2009 21
HIT, Heidelberg** Germany 250 1 gantry, 2 horiz. 2009 N.A.
UPenn, Philadelphia USA 230 4 gantry, 1 horiz. 2010 N.A.
* degraded beam for 1996 to 2006; dedicated 250 MeV proton beam from 2007 on
** with beam scanning
*** with spread beam and beam scanning (MD Anderson, since 2008)
**** degraded beam
N.A. not applicable (treatment started)
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Table 1.2: Quantities relevant for the Bethe-Bloch equation and some of their values according
to [Nak10].
Symbol Definition Units or value
dE
dx energy loss MeVg
 1 cm2
A atomic mass of medium gmol 1
NA Avogadro’s number 6.022 136 7(36) 1023mol 1
K
A 4NAr
2
emec
2=A 0.307 075 MeVg 1 cm2
for A = 1 gmol 1
zeff effective charge of incident particle
Z atomic number of medium
mec2 electron rest energy 0.510 999 06(15) MeV
I mean excitation energy eV
 density effect correction
Most important in this equation is the dependence on
1
2
and zeff . These two are key factors
to understand the appearance of protons Bragg peak near the end of their range, as emphasized
in an energy loss versus depth plot. The
1
2
' 1
E
factor yields an increasing energy loss with
decreasing particle energy, related to the time a given through-going particle is disturbing the
atomic cloud; at low energies, in turn, not only the available energy is small, but electrons
from the target are collected by the passing particle, thus rapidly decreasing its zeff . The two
contributions cause the distinct maximum of energy loss. Also, the low energy loss at higher
energies explains the quasi constant plateau of energy deposition in the entrance [Kra00]. These
characteristics can be seen in Figure 1.5 for several ions, with the stopping power displayed
with units of linear energy transfer (LET), a measure of the energy deposited in the target by
all electrons ejected by the passing particle.
Figure 1.5: Energy loss in water for several particles; after [Sch91, Cre05]. The curves were
calculated with the computer code ATIMA (atomic interactions with matter).
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Figure 1.6: Lateral broadening of a photon, carbon and proton beam; after [Web96, Kra00].
Another relevant process is multiple Coulomb scattering (MCS). Protons suffer small angles
deflections when traversing a medium due to both strong interactions and, mainly, Coulomb
interactions with target nuclei. Coulomb scattering distribution is approximately Gaussian for
small deflection angles, showing larger tails for larger angles [Nak10]. For small angles  it is
enough to use a Gaussian approximation with an angular width given by [Hig75, Kra00].
 =
14:1MeV
pc
z
s
x
X0

1 +
1
9
log10
x
X0

; (1.2)
where p is the momentum, c the velocity, and z the charge of the projectile.
x
X0
is the
thickness of the scattering medium expressed in radiation length1.
MCS has consequences both on the lateral width (Fig. 1.6) and range straggling of proton
beams (Fig. 1.3). In Fig. 1.3 the comparison between photon, carbon and proton beams shows
that carbon has the lowest beam width and that for protons the lateral scattering exceeds the
one of the photons for penetration depths larger than 7 cm. In Fig. 1.3 the smaller range
straggling of carbons in comparison to protons can be observed.
Beam lateral scattering is very important from the clinical point of view, even more than the
longitudinal scattering. That is because the treatment planning avoids the stopping of the
beam in front of the OAR due to range uncertainties and, consequently, tumor volumes close
to critical structures can only be irradiated with the beam passing by. The distance at which
the beam will pass by is determined by its lateral scattering [Kra00].
There are several published proton multiple Coulomb scattering measurements, ranging from
1 MeV to 200 GeV of incident energy [Got93].
1 Mean distance over which a high-energy electron loses all but
1
e
of its energy by bremsstrahlung [Nak10].
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Figure 1.7: Characteristic cell survival pattern for low-LET X-rays and high-LET charged par-
ticles or neutrons; from [Ger07]. Higher LET radiations increase the slope of cell survival curve,
resulting in a larger relative biological effectiveness per unit dose.
1.3.2 Radiobiological rationale
Radiation can cause damage in the tissues either by direct or indirect action. In direct action
the radiation interacts directly with the critical target in the cell (mostly DNA), ionizing and
exciting the atoms of the target through Coulomb interactions. This triggers a chain of physical
and chemical events that may, or may not, lead to the biological damage [Sun05]. Indirect
action occurs when the radiation interacts with other molecules and atoms within or in the
surroundings of the cell, producing free radicals that diffuse until reach the critical target.
In the case of indirect action, the radiation interacts mainly with water, in a process called
radiolysis, from which results short lived but extremely reactive free radicals like OH (hydroxyl
radical) [Sun05, For02].
Following the radiolysis of water other products are formed from subsequent reactions. For
example, two OH can react forming H2O2 (hydrogen peroxide). This is quite relevant because
OH, along with H2O2, is responsible for approximately two-thirds of all radiation damage
following the radiolysis of water [For02]. A known important factor that can enhance the
radiation damage is the amount of oxygen in the tissues [Hal06].
Indirect action is very important when it comes to protons, because about two-thirds of the
damage they induce is through this mechanism. This is true not only for protons but for all
sparsely ionizing radiation or low-LET radiation [Sun05]. Photons, electrons, protons, and he-
lium can be included in this category. Although protons are low-LET radiation and considered
biologically radiation equivalent to photons [DK07], the resulting biological effects substan-
tially differ, as shown in Fig. 1.7. The differences are due to the discrepancies in the relative
biological effectiveness (RBE). The RBE is defined in reference to sparsely ionizing radiation,
mostly 220 keV X-rays [ICR86, Kra00] and is the ratio of X-ray dose to particle dose that
produces the same effect (Fig. 1.8). The effect may be cell killing, mutation, transformation,
i.e., carcinogenesis, tissue damage, among other endpoints [Ger07].
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Figure 1.8: Definition of RBE, the relative biological effectiveness, illustrated with cell survival
curves; from [Kra00].
For protons, there is evidence that the RBE increases slightly throughout the SOBP, specially
in the distal one-third [Ger99, Raj95]. Carbon beams also present variations in the RBE along
their track, but at a higher scale (section 1.4). RBE > > 1 provides larger tumor-to-healthy
tissue equivalent dosage, which potentiates useful clinical applications (section 1.5). So, this
characteristic of protons can be seen as a drawback or as an advantage, depending on the
therapeutical application in view. Although protons have a smaller biological effectiveness,
this enhances simplicity of models for proton radiotherapy [Ger07].
1.4 Comparison with photons
The main advantage of protons, when compared with photons, is its inverted depth-dose profile,
as depicted in Fig. 1.3. Unlike protons and heavier charged particles, photons depth-dose
profile shows the highest energy deposition shortly after their entrance in the tissue, which then
decreases exponentially as the penetration depth increases. Fig. 1.9 compares the irradiation of
a young patient with medulloblastoma with conventional X-rays and protons. The differences
are clearly visible, with the protons avoiding the irradiation of the OAR in the vicinity of the
vertebral bodies.
Another important advantage of protons is that the beam can be driven by magnetic deflection,
which permits directing and shaping the beam without any passive components (section 1.6).
The lateral scattering of protons can also be considered an advantage in comparison to photons,
but only if the penetration depth does not exceed 7 cm (Fig. 1.6). Above that value, lateral
scattering of protons increases very steeply.
The major hindrance to the further development of proton therapy is its relatively higher cost.
It is estimated that the ratio of the costs of proton versus X-ray therapy per treatment fraction
is about 2.4 [Pag06, Goi03].
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Figure 1.9: Treatment of a young patient with medulloblastoma; from [Sui03]. The image on the
right side shows the irradiation with the conventional posterior 4 MV X-ray beam and resultant
intermediate high dose to the anterior tissues/organs. The image on the left shows the treatment
by a posterior proton beam which delivers nearly zero dose to all tissues anterior to the anterior
surface of the vertebral bodies.
1.5 Comparison with other charged particles
Although protons share some features with heavy charged particles, such as the Bragg peak,
some differences are also present. Even the Bragg peak shows dissimilarities between them,
being narrower for heavy particles because they do not suffer as much Coulomb scattering
from target nuclei as protons. However, heavy particles undergo a process called nuclear
fragmentation [Nör80] that causes an increase in the dose beyond the Bragg peak, delivering
unwanted dose distal to the tumor [Jäk06].
Heavy ions show an increasing RBE with increasing charge (Fig. 1.10). Carbon and neon ions,
in particular, show a significant difference between the RBE at the entrance and at the Bragg
peak, which allows for an enhanced dose essentially in the tumor, sparing the surrounding
healthy tissues (Fig. 1.10 for carbon). In the particular case of carbon, the most studied
heavy particle for therapy, with five currently operational centers in Japan, Germany, and
USA [pFa10] and other five already proposed or under construction [pro10], the RBE values
are between three and five at the Bragg peak for most radioresistant tumors [Cre05].
Because they are high-LET or densely ionizing radiation, heavy ions damage cells mainly
through direct action. This is an enormous advantage because it eliminates the dependence on
the presence of oxygen within the cell. Since the particles interact directly with the atoms of
the cell, they cause unrepairable damage in the DNA whether there is oxygen or not [Cre05].
Another significant advantage of heavy ions is that they may interact with the target through
a nuclear reaction , causing auto and/or target activation, and decay by + decay [Cre05].
Fortunately, the positrons emitted allow monitoring the dose delivered to the patient with
PET.
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Figure 1.10: The RBE for a fractionated irradiation of jejunal crypt cells of mice after irradi-
ation with different ions in different positions of a SOBP; from [Jäk06]. The modulation depth
of the SOBP was 8-10 cm and the initial energy was 160, 225, 400, 557, and 570 MeV/u for
protons, helium, carbon, neon, and argon ions, respectively. Proton data from [Tep77] and ion
data from [Gol81] (left). Comparison between the physical and the biological dose for carbon ions;
from [Kan99, Pag09] (right).
1.6 Equipment and facilities
The currently operating proton therapy centers are listed in Table 1.2. Some of them are
hospital-based facilities (e,g., Loma Linda, USA), others are associated physically with a na-
tional laboratory (e.g., GSI, Germany), and others are stand-alone facilities not physically
linked to any hospital (e.g., Orsay, France) [Tso07]. Nevertheless, all of them need an accel-
erator to produce the proton beams and adequate systems to perform the treatment delivery
to the patient. These topics will be discussed in this section, along with the techniques more
commonly used in proton therapy.
1.6.1 Accelerators
The accelerator used in a proton facility can be either a cyclotron or a synchrotron. A cyclotron
is a circular chamber with two ’dees’ acting like accelerating electrodes, while a magnetic field
keeps particles in a circular trajectory with crescent radius. Beam particles are injected in
the center of the cyclotron and then accelerated each time they pass through the electric field.
When the beam reaches its maximum energy it is extracted from the cyclotron and directed to
the treatment room. A synchrotron is a narrow vacuum ring tube that receives and accelerates
a beam, generally pre-accelerated by a LINAC. The main difference to the cyclotron is that
the synchrotron gradually increases the magnetic field to keep the beam within the tube as
its energy also increases. The beam is extracted when the desired energy is reached, i.e., the
synchrotron allows for energy variation [Fla07, Pag06].
Within a facility, an accelerator is generally used to serve more than one treatment room
(Fig. 1.11). Clinical parameters such as dose rate, range, distal fall-off, and lateral penumbra
are directly affected by the beam current, beam energy, the beam energy spread, and the
beam size, respectively. Therefore it is important to assure that the accelerator is optimized
for production of the intended clinical beams and delivery modalities. For example, if passive
beam shaping (section 1.6.2) is used, the clinical parameters are also influenced by the materials
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used to modulate the beam, so adjustments to the accelerator beam parameters will eventually
be needed.
With the growing interest in proton therapy, there is the need of developing smaller cyclotrons
that can be affordable to more medical centers. Since there is an evolution from therapy centers
physically associated with a laboratory for physical research to hospital-based facilities, it is
also needed that accelerators are designed according to this new reality. This should comprise,
besides building more compact accelerators, designing equipment that allows for maintenance
to keep a high reliability, investing in new methods of acceleration and improving treatment
segments to allow more on-treatment adjustments to dose delivery, among other things.
Figure 1.11: Floor plan of the Loma Linda University Medical Center’s Proton Treatment
Center, Loma Linda, CA, USA, with three gantry rooms and another with horizontal beams;
from [Ama10]. The 7 m diameter synchrotron built by Fermilab accelerates the protons up to 250
MeV (top). Floor plan of the Heavy-Ion Therapy (HIT), Heidelberg, Germany, with one gantry
room and two others with horizontal beams; from [Lag07] (bottom).
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Figure 1.12: The nozzle at Francis H. Burr Proton Therapy Center, Boston, MA, USA;
from [Pag04]. Beam monitoring devices are ionization chambers and a range verifier (multi-layer
Faraday cup). Beam-shaping devices are scattering systems, range modulators, and wobbling
magnets. Variable collimators (’jaws’) and the snout determine the field size.
1.6.2 Treatment delivery systems
After the beam is extracted from the accelerator, it must be directed to the treatment rooms
and to the patient. This is made through magnets for bending, steering and focusing. The
treatment room can have either a fixed horizontal beam line or a full rotating gantry. The
former allows only the irradiation of the patient in seated or near-seated positions, whereas
the latter allows delivering the beam from any angle, which is of great importance when it
comes to conformal radiation therapy. Gantries are quite large, typically with up to 10 m
of diameter, for two reasons. First, protons at therapeutical energies require large radii to
be bent, and second, they have to accommodate in their nozzle all the components for beam
shaping and beam monitoring. Beam shaping devices include scatterers, absorbers, and other
patient specific hardware [Fla07, Pag06]. Fig. 1.12 depicts the components of a nozzle in the
Francis H. Burr Proton Therapy Center, formerly Northeast Proton Therapy Center (NPTC).
Passive beam shaping
Passive beam shaping and pencil beam scanning (or raster scanning) can be used to modulate
the beam so it covers all the planning treatment volume (PTV). Passive shaping currently
dominates clinical use because it is simpler to use than active systems (section 1.6.2), which
use magnetic deflection to control the beam. In passive beam shaping the beam is spreaded out
with scatterers to cover the field cross section. The SOBP is produced modulating the energy of
the beam with range modulators like ridge filters, range-modulator wheels, and range shifters.
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Additional modulation of the beam can be achieved using apertures and range compensators
specific for each patient. Different combinations of these components are made in order to
accomplish the desired dose distribution. However, care must be taken with the position (i.e.,
upstream or downstream) and the number of devices used, because there is the risk that dose
sharpness is degraded and lateral penumbra augmented [Got07, Ped00, Pag06].
Another form of modulation can still be used with passive shaping, beam gating and current
modulation. It consists, essentially in turning off the beam during part of the revolution, and
varying the beam current during the modulator cycle, respectively, thereby reducing the high
number of range modulators, apertures, and range compensators required to satisfy the needs
of all patients [Got07].
Active beam shaping
Although it is still restricted to a few centers, the trend is towards the increase in the use of
pencil beam scanning. Currently, only the PSI, the MD Anderson Cancer Center, the Francis
H. Burr Proton Therapy Center, the RPTC, and the HIT have this technique available, but
there are others already considering it [Nau10].
In pencil beam scanning, a narrow beam of protons is made to enter the patient at different
locations by deflecting the beam under magnetic control. Although it is more complex, this
avoids the considerably high number of devices utilized to modulate the beam with passive
beam shaping, because it is usually applied without field- or patient-specific hardware, and
under computer control. This brings other advantages like the reduction of the infrastructure
for manufacturing and storing passive components, and the simplification of patient positioning,
thereby diminishing the required treatment time. Also, the absence, or reduced number, of
field-specific devices lowers the activation of the material near the patient [Ped00, Ped07].
Figure 1.13: Example of intensity modulated therapy with photons (left) and spot scanning with
protons (right); after [Ped00]. The yellow contours represent the targets (the visible tumor, the
treatment volume with involved limph nodes). The red lines represent OARs to spare (salivary
glands, brain stem). The dose distribution for photons (shown with color shading in percentage of
the dose) is obtained through the superposition of 9 convergent photon fields. The dose distribution
for protons is obtained this time with only 4 fields. The advantage compared to photons is the
reduction of the dose outside the target volume.
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Beam scanning manages to achieve a true 3D conformal dose distribution, conforming to the lat-
eral, distal, and, in contrast to passive shaping, to proximal dimension of the PTV, preventing
the delivery of unwanted dose to healthy tissues. The major disadvantage of pencil beam scan-
ning in comparison with passive shaping is its higher sensitivity to organ motion [Ped00, Ped07].
Beam scanning is a subset of and intrinsically promotes the delivery of intensity-modulated
proton therapy (IMPT) fields, which is analogous to intensity-modulated radiation therapy
(IMRT) for photons. In IMPT, a single field delivers an inhomogeneous dose and the final
homogeneous target dose is achieved only with multiple fields. IMPT allows designing and
delivering dose to PTVs with complex shapes, even with convexities and holes. [Ped07]. The
difference for IMRT is that it is possible to vary the energy of each pencil beam in addition to
its intensity [Pag06]. Fig. 1.13 shows the distinct dose distributions obtained with IMRT and
IMPT.
A specific modality of pencil beam scanning is spot scanning, which consists in delivering dose
only in specific static positions, i.e., the beam moves without delivering dose until it reaches
a particular position where the dose is delivered [Ped07]. It is simpler to use than raster
scanning but, in turn, irradiation with this technique requires a higher amount of time and it
is error-prone due to difficulties in achieving a highly uniform dose.
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Chapter 2
Simulation Tools for the Development
of a Proton Radiobiological Setup
2.1 Geant4 and SRIM/TRIM
The code for this work was implemented using Geant4 (Appendix A) [Ago03, All06]. Geant4
is an acronym for geometry and tracking and is based on Monte Carlo. First validations of the
code were made against SRIM/TRIM (Appendix A) [Zie08]. SRIM stands for stopping and
range of ions in matter and it is a group of programs which calculate the stopping and range
of ions [SRI10]. TRIM is an acronym for transport of ions in matter and a computer program
also based on Monte Carlo that calculates the interactions of energetic ions with amorphous
targets [Zie08].
2.2 Validation of Geant4
The code used in this work is based on a hadrontherapy example from Geant4 and it was
developed by G.A.P. Cirrone, F. Di Rosa, S. Guatelli, and G. Russo from Laboratori Nazionali
del Sud of the National Institute for Nuclear Physics, Catania, Italy, and National Institute
for Nuclear Physics Section of Genova, Genova, Italy. It was created in May 2005.
We used several setups for validating our code. We wanted to make sure we would obtain
trustable results with it. As that, we did one validation for proton range, and another for
beam lateral scattering.
2.2.1 Proton range
The setup depicted in Fig. 2.1 was used for validation of proton range in water. The water
target thickness was chosen based on a first calculation with SRIM, from which resulted a
projected range of 3.45 mm. So we proceeded to the simulation of a 18-MeV proton beam
hitting a 5-mm long water target. We used an ideal source and put both the target and the
source within a spheric perfect detector so that particles eventually leaving the target could
be detected. It is important to notice that the detector is in vacuum and not in air. This
consideration was made for simplification reasons, as we are interested solely, in this case,
in determining the proton range in water. Furthermore, SRIM/TRIM calculations are also
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Figure 2.1: Schematic representation of the simulation setup used for proton range validation.
A water target with dimensions 1x1x5 mm is in the center of a 300-mm radius spheric perfect
detector in vacuum. The distance between the point source and the water target center is 160 mm.
The beam travels along the Z positive direction.
Figure 2.2: Range in water for 18-MeV protons, obtained using TRIM software. The simulation
consisted in 99 999 pencil-beam shaped 18-MeV protons hitting a 5-mm long liquid water target
with an angle of incidence of 0°.
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idealized, considering that protons enter directly in the water target. So, vacuum is the most
adequate ’medium’ to compare simulation data of both SRIM/TRIM and Geant4.
Figure 2.3: Range of 18-MeV protons in a 5-mm long water target. Top: depth profiles obtained
with Geant4 (solid) and SRIM/TRIM (dashed). Bottom: Geant4-based 2D distribution. The
Geant4 simulation consisted in 9 million pencil-beam shaped 18-MeV protons hitting the target
in vacuum. The arrows point out the region where the energy of the projectiles falls below
the Coulomb energy for collisions with target oxygen. Consequently, lateral straggling is highly
enhanced passed this point.
Range validation was made against data obtained with TRIM. Fig. 2.2 shows the result of a
TRIM simulation for 18-MeV protons range in water. These data were compared with Geant4
simulation outcome. The concordance between both curves can be observed in Fig. 2.3 (top),
although Geant4 results show a higher number of particles that stopped at the entrance plateau
before Bragg peak due to higher statistics (Geant4 was simulated with 9 million pencil-beam
shaped protons and TRIM with only 99 999). The bottom graph of the Fig. 2.3 shows the
resulting 2D distribution of protons in water from Geant4 simulation. It can be observed here,
as well as in the top graph, a decrease in the number of particles that stopped just before
the Bragg peak. This is due to the the decrease of protons energy below Coulomb energy for
collisions. In consequence, passed this point, there is a significant increase in lateral scattering,
which will be discussed in the next section.
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2.2.2 Proton beam lateral scattering
The setup used for validation of beam lateral scattering is depicted in Fig. 2.4. The difference
for the setup in Fig 2.1 is target thickness, which is 1.5 mm in this case. This thickness was
chosen to allow protons to interact with the target long enough to suffer Coulomb scattering,
and then leave the target, being detected in the spheric perfect detector. Once again, the
source is a point source and the detector is in vacuum for simplicity reasons.
Figure 2.4: Schematic illustration of the simulation setup used for proton beam width validation.
The water target with dimensions 1x1x1.5 mm is in the center of a 300-mm radius spheric perfect
detector in vacuum. The distance between the point source and the water target center is 160 mm.
The beam travels along the Z positive direction.
Validation is done against Equation 1.2. Values used for calculating  are listed in Table 2.1.
1
X0
for water is obtained summing the contributions from
1
X0
for oxygen and hydrogen (equa-
tion 2.1), yielding an equivalent value to tabulated X0 for water, 36.08 g/cm2.
18
X0(H2O)
=
2
X0(H)
+
16
X0(O)
; (2.1)
The theoretical value obtained for  was an angle of 1.2293.
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Table 2.1: Some of the values used for calculating beam lateral scattering.
Quantity Value Units
 0.196815
p 184.667485 MeV/c
c 299792458a) m/s
z 1
x 0.15 g/cm2
X0(H) 63.0470b) g/cm2
X0(O) 34.2381b) g/cm2
a) According to [Nak10].
c) According to [Tsa74].
Data was fit with a pseudo-Voigt1 function and the result corresponds to the blue curve in
Fig. 2.5. The parameters used in the fit are listed in Table 2.2.2. The fit yielded a  value
of 1:3678 0:0045 (338 iterations), which represents a difference of about 11.3% in respect to
the theoretical value calculated.
Table 2.2: Parameters used to fit the simulated data to a pseudo-Voigt function.
Name Value
ConstantG 80000
Mean 0
Sigma 1.35
Pedestal 0
Slope 0
ConstantL -1500
Width -2
Peak 4
This result may seem somewhat high, since dosimetry requires accurate outcomes. However, if
we compare the theoretical value already calculated with the one obtained with another well-
established expression, like equation 2.2 [Hig75, Hig79, Cre05], which yields a  of 1.0945,
a similar discrepancy can be observed. This value corresponds to a difference of nearly 10.9%
in respect to the one calculated with equation 1.2. The reason for these uncertainties in 
values obtained with both expressions can be explained by the fact that such expressions are
obtained by adjustments made to beams with no negligible width.
 =
13:6MeV
pc
z
r
x
X0

1 + 0:038 ln

x
X0

; (2.2)
1 A Voigt function is the convolution of a Gaussian function and a Lorentzian function. As it requires a
relatively involved computational procedure, it is often replaced by a pseudo-Voigt function, which consists
in the weighted sum of a Gaussian function and a Lorentzian function [Ver06].
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Figure 2.5: Proton beam lateral scattering. Angular distribution of 18-MeV protons after travers-
ing 1.5-mm long water target. The simulation consisted in 25 million pencil-beam shaped protons
hitting the target in vacuum.
Chapter 3
Concept for a Proton Cyclotron-Based
Radiobiology Facility
Although it may be suitable for other cyclotron-based facilities, the setup described and studied
in this work is planned to be implemented at one of the beam lines of the cyclotron recently
installed at Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), University of Coimbra.
As that, it is important to know some of its features, which will be described briefly. The
chronology of such information is also relevant in order to understand the sequence of this
work.
After the first code validations, described in the previous chapter, what we will be doing here
is a systematic approach with Geant4. We simulate the dose delivered by the cyclotron beam
and study how dispersion influences it.
Figure 3.1: Dose-response curve for tumor control probability and normal tissue damage prob-
ability; from [Hal06]. The dose-response relationship is sigmoid in shape for both tumor control
and normal tissue damage. That for normal tissue damage may be steeper than for tumor control.
The therapeutic ratio (or index) is the percent of tumor control that can be achieved for a given
level of normal tissue damage. In this hypothetical example, about 30% tumor control can be
achieved for a 5% incidence of normal tissue damage.
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The dose calculated in this work is the absorbed dose. Independently of the number of protons
simulated, the depth-dose curves obtained correspond to the dose delivered by one million pro-
tons hitting the target. In radiotherapy, the accurate determination of this quantity is crucial
due to the relatively steep sigmoidal dose-response curve for both tumor control and normal
tissue damage (Fig. 3.1) [Nah07b]. Absorbed dose is a non-stochastic quantity applicable to
both indirectly and directly ionizing radiations and is related to the stochastic quantity energy
imparted. The absorbed dose is defined as the mean energy " imparted by ionizing radiation
to matter of mass m in a finite volume V by [Seu05, Nah07b, ICR80, ICR98]:
D =
d"
dm
(3.1)
The energy imparted " is the sum of all the energy entering the volume of interest minus all the
energy leaving the volume, taking into account any mass-energy conversion within the volume.
The unit of absorbed dose is joule per kilogram (J/kg). The name for the unit of absorbed
dose is the gray (Gy).
3.1 ICNAS cyclotron
The cyclotron installed at ICNAS is manufactured by IBA (Ion Beam Applications, S.A.,
Belgium) and is a Cyclone® 18/9 HC, a fixed-energy cyclotron that accelerates protons and
deuterons. Initial informations about beam energy were gathered in IBA’s website, which
indicates that protons are accelerated up to 18 MeV and deuterons up to 9 MeV [IBA10]. Later,
in a private communication, we became aware of details about the beam port design, namely
that it is composed of several materials, through which the beam has to pass before leaving the
the cyclotron. The first one is a thin foil (approximately 50 m) of Havar® (Appendix B) to
keep the necessary low operating pressure inside the cyclotron; then, there is a chamber with
gaseous helium that acts as a cooling system; in the other end of the chamber another material
is placed, usually a thin foil (approximately 12 m) of aluminum or titanium, to make the
separation between the helium and the exterior of the cyclotron, to support the target and to
act as a thermal interface between the helium and the target. In the context of the same private
communication, a first approximation was made to what would be the beam dispersion, and the
conclusions were that the beam would have a nearly Gaussian distribution with a FWHM (full
width at half maximum) of 10 mm after 30 cm. Also, an estimed value was given for the beam
energy after traversing these materials, which would be around 17 MeV for protons [Alv10a].
Through a contact with IBAMolecular, more precise specifications were obtained: the cyclotron
is capable of accelerating protons up to 18.5 MeV and deuterons up to 9.2 MeV with beam
currents equal to 150 A and 40 A, respectively; both beams present an approximately
Gaussian distribution, with 80% of protons and 70% of deuterons within 10 mm and a dispersion
of 3 and 4, respectively; and the energy of the beam after leaving the port is 17.5  0.2 MeV
for protons and 8.2  0.1 MeV for deuterons [Alv10b].
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Figure 3.2: Concept of the experimental setup being planned at one of the beam lines of the
cyclotron of the University of Coimbra. A moving range modulator allows for a controlled decrease
in beam energy below 18 MeV. A shutter-equipped collimator with adjustable hole size follows. It
regulates both beam lateral size and time exposure which, consequently, allows for the control of
the area and dose delivered to the target. The target may consist of cell cultures, small animals,
or dosimetric devices enabling the characterization and control of beam parameters.
3.2 Design proposal
Fig. 3.2 depicts the first draft of the experimental setup being planned, which will allow per-
forming radiobiological studies either with cell cultures or small animals. It is composed of
several devices, namely a moving range modulator, a shutter-equipped collimator, and a sup-
port system for the target. The range modulator permits decreasing the beam energy below
18 MeV; the collimator has an adjustable hole size, which permits controlling the area being
irradiated; and the shutter associated with the collimator regulates time exposure and, thus,
the dose delivered to the target.
3.3 Influence of beam divergence on dose delivery
3.3.1 Pencil beam
In a first phase of this study we did simulations with 18-MeV pencil-beam shaped protons
hitting a water target, using the setup depicted in Fig. 2.1. The depth-dose profile in Fig. 3.3
is the one resulting from such simulation. It can be observed that the peak in this curve
matches the simulated Bragg peak in Fig. 2.3, since it is verified at 3.449 mm. The dose at the
peak is 2.9605 Gy.
Following this simulation, the next step was to introduce a small variation in water target
density in order to study the influence of target density variation in depth-dose curves. This
way we would be able to verify if and how such variation would affect the location of the peak
into the target. Using the same setup (Fig. 2.1), but changing the water density from 1.00 g/cm3
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Figure 3.3: Depth-dose profile in water for 18-MeV protons. The curve peak is 2.9605 Gy for a
depth in water of 3.449 mm. The simulation consisted in 9 million pencil-beam shaped 18-MeV
protons hitting the target in vacuum.
to 1.05 g/cm3, which means a difference of 5%, we obtained the depth-dose profile represented
with a dashed blue line in Fig. 3.4(a). It can be observed that the curve peak is shifted to
the left. It has now a value of 2.9619 Gy at 3.286 mm, which corresponds to a difference of
163 m in respect to the solid black curve peak. When we were informed about the actual
proton beam energy after leaving the beam port, 17.5 MeV, we used the same setup (Fig. 2.1)
to make an identical simulation and determine the depth-dose profiles for protons with this
energy. The resulting curves are shown in Fig. 3.4(b). In this case, the peaks are situated at
3.281 mm and 3.124 mm for the solid black line and the dashed blue one, respectively. The
correspondent values of dose are 3.0189 Gy and 3.0234 Gy.
Fig. 3.5 compares the depth-dose profiles in water of regular density for 18-MeV and 17.5-MeV
protons. It can be noticed that protons with less energy (dashed red line) have a smaller range
in the same target.
In face of these results, we wanted to check if and with which proportions this phenomenon
would occur for higher energies. So we made a simulation using the setup depicted in Fig. 3.6.
The resulting dose profiles are shown in Fig. 3.6. Also in this case, it can observed that the
peak of the depth-dose profile corresponding to the water target with 1.05 g/cm3 is shifted to
the left. The difference in this case is of 12.038 mm.
3.3.2 Beam with dispersion
After the private communication in which we were given a first approximation of what would
be the beam dispersion [Alv10a], we started making simulations taking this variable in account.
We calculated an angle of dispersion of 0.95484 for a FWHM of 10 mm at 30 cm. Also, we
changed the beam energy to 17 MeV and considered a circular source with a radius of 1 mm.
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(a) 18-MeV protons.
(b) 17.5-MeV protons.
Figure 3.4: Influence of density variation on depth-dose profile in water for 18-MeV and 17.5-MeV
protons. The solid black curve is the depth-dose profile in water with a density of 1.00 g/cm3 and
the dashed blue one is the depth-dose profile in water with a density of 1.05 g/cm3. The simulations
to obtain these curves consisted in pencil beam shaped protons hitting the correspondent water
targets with 5% difference in density. The total number of protons was 9 million for (a) and 8
million for (b). (a) The peak for the solid black curve is 2.9605 Gy at 3.449 mm and, for the
dashed blue curve, it is 2.9619 Gy at 3.286 mm, which corresponds to a difference of 163 m
between both peaks. (b) The peak for the solid black curve is 3.0189 Gy at 3.281 mm and, for the
dashed blue curve, it is 3.0234 Gy at 3.124 mm, corresponding to a difference of 157 m between
both peaks.
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Figure 3.5: Influence of proton beam energy on depth-dose profile in water. The solid black curve
represents the depth-dose profile in water for 18-MeV protons and the dashed red line corresponds
to the same profile for 17.5-MeV protons. These curves are the same represented by the solid black
line in Fig. 3.4(a) and (b), respectively.
Figure 3.6: Schematic representation of the simulation setup used for irradiating water with
200-MeV protons. A water target with dimensions 5x5x300 mm is in the center of a 300-mm
radius spheric perfect detector in vacuum. The distance between the point source and the water
target center is 300 mm. The beam travels along the Z positive direction.
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Figure 3.7: Influence of density variation on depth-dose profile in water for 200-MeV protons.
The black curve is the depth-dose profile in water with a density of 1.00 g/cm3 and the blue one
is the depth-dose profile in water with a density of 1.05 g/cm3. The peak for the black curve
is 7.1170 mGy at 254.958 mm and, for the blue curve, the dose in the peak is 7.4487 mGy at
242.920 mm. This corresponds to a difference of 12.038 mm between both peaks. In both cases,
the simulation consisted in 400 thousand pencil-beam shaped protons hitting a water target. The
difference was the water density, which was 5% higher for the dashed blue curve.
Several setups were used for the simulations in this phase. We first simulated the effect of beam
dispersion in a cylindric water target. The correspondent setup is represented in Fig. 3.8. The
result is shown in Fig. 3.9(a). Looking at these curves one can see that the dose is higher within
a radius equal to 1 mm and decreases as the radius increases, meaning that the dose is delivered
mainly in the center of the target, even in the case of a beam with dispersion. Fig. 3.9(b)
represents the same depth-dose profiles in the same target but for 17.5-MeV protons. This
simulation was made after we were told the beam energy after traversing the material in the
beam port is 17.5 MeV.
The following step was to study dose 3D distribution. We used the setup depicted in Fig. 3.10,
in which there is a parallelepiped of dimensions 50x50x15 mm that is hit by protons. The dose
in this target is registered in each 100 m cube. The resulting 2D distribution from simulations
with this setup, and the correspondent profile, is shown in Fig. 3.13.
Havar® target
At the time we got the information that the beam energy after leaving the beam port is
17.5 MeV, we were also informed that Havar® is the main responsible for beam disper-
sion [Alv10b]. As that, we used the setup depicted in Fig. 3.12 to study the influence of
Havar® on dose. This setup uses the same source and beam dispersion considered in the pre-
vious case, but between the source and the target, at a distance of 300 mm from the source
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and 150 mm from the water target, there is a 50-m-long Havar® foil.
Figure 3.8: Schematic representation of the simulation setup used for first simulations of a beam
with dispersion. A 25-mm radius and 10-mm long cylindric water target is in the center of a
300-mm radius spheric perfect detector in vacuum. The distance between the circular source and
the water target center is 300 mm. The beam travels along the Z positive direction with 0.95484
dispersion.
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(a) 17-MeV protons.
(b) 17.5-MeV protons.
Figure 3.9: Depth-dose profiles in water at four different radius for 17- and 17.5-MeV protons.
The dotted dashed black line is the depth-dose curve for a 1-mm radius cylindric water target,
the dotted blue line is the one for a 5-mm radius, the dashed purple line for a 10-mm radius and
the solid red line for a 25-mm radius. The simulations consisted in 1 million pencil-beam shaped
17-MeV (a) and 17.5-MeV (b) protons with dispersion from a 1-mm radius circular source hitting
25-mm radius cylindric water target in vacuum.
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Figure 3.10: Schematic illustration of the simulation setup for calculating the dose 3D distribu-
tion. A water target with dimensions of 50x50x15 mm is in the center of a 300-mm radius spheric
perfect detector in vacuum. The distance between the circular source and the water target center
is 307.5 mm. The beam travels along the Z positive direction with 0.95484 dispersion.
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Figure 3.11: Depth-dose profile (top) and 2D distribution (bottom) of 17-MeV protons in water
in the target central slice (left) and in the entire target (right).
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Figure 3.12: Schematic illustration of the simulation setup for studying the influence of
Havar® on dose 3D distribution. A water target with dimensions of 70x70x15 mm is in the
center of a 450-mm radius spheric perfect detector in vacuum. Between the source and the target
there is a 50-m-long Havar® foil. The distance between the circular source and the Havar® foil
center is 300-mm. and the distance between the water target center and Havar® is 150 mm. The
beam travels along the Z positive direction with 0.95484 dispersion.
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Figure 3.13: Influence of Havar® on depth-dose profile (top) and 2D distribution (bottom) of
17-MeV protons in water in the target central slice (left) and in the entire target (right).
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Chapter 4
Conclusions
4.1 Work results
This work is focused on cyclotron proton beams for radiobiology. The scientific basis of a
viability study for the implementation of a cyclotron-based radiobiology facility, considering
an 18-MeV proton cyclotron, and particularly the one installed at ICNAS. We started from an
already structured Geant4-based code and validated it against well-established Monte-Carlo
based codes, as SRIM/TRIM, and theoretical expressions, as equation 1.2. Then, we continued
manipulating the code to yield dose profiles and 2D distributions.
We can therefore divide this work in two main phases, the validation phase and the dose
estimation phase. All work following validation was strongly influenced by the sequence of the
informations about the cyclotron beam characteristics.
During the first phase, simulations were performed to validate the code for either proton range
and proton beam lateral scattering. The former was validated against data from SRIM/TRIM
and the latter against the theoretical  of proton angular distribution, predicted by equa-
tion 1.2. Proton range was clearly validated, as seen in Fig. 2.3. The curve correspondent
to simulated data remarkably matches the curve correspondent to data obtained with TRIM.
Also, either in Bragg curve and in 2D dose distribution of Fig. 2.3 it is possibly to observe
a depression right before the Bragg peak, which corresponds to the decrease of protons en-
ergy below Coulomb energy for collisions with target oxygen. Passed this point, protons are
scattered mainly by interactions with target nuclei. Beam lateral scattering was also validated
considering the theoretical expected values.
The second phase itself can be subdivided in several parts, not necessarily subsequent to each
other. Right after code validation we began to run simulations to build dose profiles obtained
with pencil beam protons from ideal point sources. This would give us a reference for compar-
ison when calculating doses delivered by beams with dispersion from non-ideal sources. Using
beams and sources with these properties, we also did simulations to study the effect of target
density variation on depth-dose profiles. Fig. 3.4 and Fig. 3.7 show such effect for different
beam energies. One can observe that density variation influences depth-dose curves peak loca-
tion and that such influence is higher for higher energies, i.e., the difference in peak location is
equal to some micrometer in case of proton energies of about 18 MeV, whereas it corresponds
to more than a centimeter if the beam energy is 200 MeV.
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This a very important result because variations in human tissue density can also occur during
a radiotherapy treatment with several sessions (fractionated radiotherapy). If such variations
are not taken into account between sessions, then one can be irradiating healthy tissue with-
out being aware and creating cold spots in the tumor. This difference is crucial because an
insuffiecient irradiation in the tumor contributes to its relapse and dose in the healthy tissue
induces undesirable side effects, including potential late cancer.
The simulations using beams with dispersion from non-ideal sources were an approximation to
the cyclotron beam characteristics. They were based on the first estimation of beam dispersion
and energy after leaving the target [Alv10a]. There were several simulations made using these
considerations. The first meant to study the depth-dose profiles in four distinct radius of a
cilindric water target for a beam with dispersion (Fig. 3.9). From it we can conclude that the
dose is far more concentrated in small radii, being around 10 times higher in a 1-mm radius
than in a 25-mm radius. The results are similar for 17- and 17.5-MeV proton beams, the peak
being slightly shifted to the left for 17-MeV protons.
Another set of simulations took place for calculating dose deposition in 3D. The dose was
registered voxel by voxel, these being 100-m3 cubes (Fig 3.13). A comparative study was
made to analyze the dispersion caused by Havar®. Further corrections were not made, like
simulating beam dispersion after passing through set of materials in the beam port (section 3.1)
due to lack of time and computational resources. Nevertheless, such simulations allow us to
have a first glance on dose values delivered by cyclotron beams to a water target.
The overall conclusion of this simulation work is that the cyclotron beam dose is too high for
using in radiobiology. With a current of 150 A, the flux is around 11015 protons per second.
All doses calculated in this work are for 106 protons hitting the target. So, in order to estimate
which dose will be delivered by 1  1015 proton, we must multiply the doses by 109. This
means the result would be, in most cases, doses of GGy in only one second (for the case of an
unrealizable, perfectly shaped pencil-beam).
The particular case of the calculus of 3D dose is the one with more interest because we can get
the maximum dose in a 100 m voxel of the target and it is that value we will use from this
point on for our calculus. Our reference is the standard value for fractionated radiotherapy,
which is 2 Gy per fraction [Ste07a]. In case Havar® is not present, the maximum dose for 106
protons is 0.0278234 Gy. Multiplying this by 109, we obtain 27.8234106 Gy. This is a very
high value of dose to be delivered in only one second. In case Havar® is present, the maximum
dose for 106 protons is 0.00383697 Gy. Multiplying by 109, we get 3.83697106 Gy. It is nearly
10 times smaller than the previous value, but it is still too high.
One way to overcome this excessive dose is to reduce cyclotron beam current. If we consider a
current of 15 A instead of 150 A, the dose will also decrease 10 times. So, we get 2.78234 MGy
without Havar® and 0.383697 MGy with it. Another solution to reduce even further these
values may be to deviate the target from the beam center and make use of beam fringes,
since we have already concluded that it is in the center that more dose is delivered (Fig. 3.9).
Fig. 4.1 represents a way to make it possible. When leaving the cyclotron, the beam is, as
already mentioned, approximately Gaussian with 80% of protons within 10 mm. Admitting
that 10% of particles are beyond 5 mm on each side of the beam axis, we can make use of
such particles to irradiate the target. The distance from cyclotron to the slit center was set as
2.4 m.
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Figure 4.1: Schematic representation of a setup configuration to allow for the delivery of low
doses. The target is situated under the rotating disk, which is, in turn, deviated from the beam
axis. The rotating disk, with 350-mm radius, has a slit of 1-mm width and R = 300 mm. The
distance from cyclotron exit and the slit center is 2.4 m.
4.2 Future work
This study had as goal to study the viability of implementing a setup at ICNAS. Further work
shall be performed to confirm and re-evaluate the conclusions presented here, there are some
things that can be done.
The code used is based on a hadrontherapy example from Geant4 from 2005. When running
the simulations in Geant4 9.3, in the verbosity there were messages alerting for the fact that
some classes are already obsolete and that they will be removed with the next major release
of Geant4. So, our code must be updated and we may try to run the same simulations we did
here using other physics and compare the outcomes.
One of the possibilities that may arise from the implementation of this setup is the chance
to determine the accuracy of proton range using post-treatment PET [Kno10]. This can be
done because positron-emitter and gamma production reactions occur when protons hit a
target [Bee03]. Table 4.1 lists some of the most relevant of those reactions.
Positrons resulting from these reactions can be detected with the RPC-PET (resistive plate
chamber1-PET) that is being developed at Laboratório de Instrumentação e Física Experimen-
tal de Partículas (LIP) [Bla06]. Its submillimetric spatial resolution and high sensitivity makes
it a potential dedicated animal PET.
The results achieved with the simulation code showed that this project is now at the stage
where a next-step, full-setup implementation can be fullfilled.
1 The resistive plate chamber is a gaseous particle detector developed for high energy physics.
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Table 4.1: Relevant positron-emitter production reactions; from [Bee03].
Nuclear Threshold energy Half-life Positron Max.
reactions (MeV) time Energy (MeV)
16O(p,pn)15O 16.79 2.037 1.72
16O(p,2p2n)13Na) 5.66c) 9.965 1.19
14N(p,pn)13N 11.44 9.965 1.19
12C(p,pn)11C 20.61 20.39 0.96
14N(p,2p2n)11Ca) 3.22c) 20.39 0.96
16O(p,3p3n)11Cb) 27.50c) 20.39 0.96
a) (p,2p2n) is inclusive of (p,)
b) (p,3p3n) is inclusive of (p,  pn)
c) Listed thresholds refer to (p, ) and (p,  pn)
Appendices
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Appendix A
Software and hardware used
A.1 Hardware
Machines used for performing the simulations necessary to this work are listed in Table A.1).
Table A.1: Machines used to perfom the simulations
Number RAM
CPU of cores memory
Machine 1 Intel® Pentium® Dual-Core T4200 2.0GHz 2 4 GB
Machine 2 Intel® 2140 1.60GHz 2 4 GB
Machine 3 Intel® Core™ 2 Quad Q6600 2.40GHz 4 4 GB
A.2 Geant4 simulation toolkit
Geant4 is a Monte-Carlo based software toolkit that simulates the passage of particles through
matter [Ago03, All06]. It is a very flexible solution with innumerous models of physics pro-
cesses in a wide range of energies [Ago03]. It can cover hadronic, electromagnetic and op-
tical interactions and has libraries to a large set of materials, elements and long-lived parti-
cles [Ago03, All06]. It is designed to be used as object-oriented language and is implemented
in C++ [Ago03].
The hadronic interactions with Geant4 are divided in three major groups: (1) cascade state,
(2) pre-equilibrium state, and (3) equilibrium state. Each state has its own models, but for
some cases it is not necessary to have a model for each state. For example, interactions at
low energy (< 100 MeV) can be modelized without the cascade phase [Wri10, Ago03]. The
cascade state describes the intra-nuclear projectile-nucleon and nucleon-nucleon interactions
after the projectile enters the nucleus. The two main models for this phase are the Bertini
cascade and binary cascade. The main code for modelization of pre-equilibrium state is the
precompound model that takes a nucleus from a highly-excited set of particle-hole states down
to equilibrium energy by emitting protons, neutrons, deuterons, tritium nuclei, helium-3 nuclei,
and alphas [Wri10]. The final phase, the equilibrium state, is known also as nuclear evaporation
or nucleus de-excitation phase. After the pre-equilibrium phase, the nucleus is supposed to be
left in an equilibrium state, in which the excitation energy is shared by a large number of
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nucleons. If the excitation energy is higher than the separation energy1, it can still eject
nucleons and light particles (deuterons, tritium nuclei, helium-3 nuclei, and alphas) [Gea09].
The generalized evaporation model (GEM) is an example of an evaporation model.
A.3 Other software
Other software used is listed below:
 Operating system: openSuse 11.2 64-bit version (Linux kernel 2.6.31.12)2
 Library for high energy physics: CLHEP version 2.0.4.5.
 C++ compiler: GCC version 4.4.1
 Geant4 visualization system: HepRApp version 3.15.0
 Data analysis: ROOT framework version 5.26/00 and IDL version 7.0.6
1 Separation energy is the energy needed to remove a nucleon or other particle from a nucleus
2 Other versions of openSuse were also used, but almost all simulations were done with openSuse 11.2 64-bit
version
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Appendix B
Havar®
Havar® was originally developed in the late 1940’s by the Hamilton Watch Company as an ’un-
breakable’ mainspring material [Rob03]. As watches moved from spring to battery power, thin
Havar® strip found a second life in high strength, non-magnetic, corrosion resistant pressure
sensing diaphragms for process control equipment [Rob03].
According to the technical sheet of Havar® [HPM], this material is a heat treatable cobalt
base alloy that provides very high strength. The alloy has excellent corrosion resistance and is
non-magnetic. Applications have included pressure diaphragms, power springs, gap spacers in
magnetic heads, and target foils in nuclear physics [HPM].
Table B.1: Nominal composition of Havar®. After [HPM].
Element Elemental percentage
Cobalt 42.0%
Chromium 19.5%
Nickel 12.7%
Tungsten 2.7%
Molybdenum 2.2%
Manganese 1.6%
Carbon 0.2%
Iron Balance
Table B.2: Physical properties of Havar®. After [HPM].
Property Value
Density 8.304 g cm 3
Melting point 1480℃
Electrical resistivity @ R. T. 92.0 
 cm
Thermal expansion coefficient (0℃ to 50℃) 12.5  10 6 ℃ 1
Thermal conductivity 13.0 W m 1 K
Magnetic attraction none
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